NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company that accessed the public markets through its merger with Big Rock Partners Acquisition Corp, a blank-check vehicle sponsored by Big Rock Partners. The company filed an S-1 registration statement on June 25, 2021, bearing accession number 0001193125-21-200558, in connection with its post-merger public-company standing. NRX operates in the pharmaceutical and biotechnology sector, with a pipeline concentrated on central nervous system disorders and critical care, including treatments for bipolar depression and respiratory failure. Big Rock Partners Acquisition Corp completed its SPAC IPO in 2019. For the full filing history, sponsor profile, and deal analytics on NRXP, sign up for complete data access at SpacDesk.